{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:07:05Z","timestamp":1785870425416,"version":"3.56.0"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Promius Pharma"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jconrel.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T12:50:35Z","timestamp":1555505435000},"page":"130-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments"],"prefix":"10.1016","volume":"305","author":[{"given":"Anusha","family":"Pusuluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Mitragotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.04.020_bb0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000262808","article-title":"The role of combination chemotherapy in the treatment of patients with metastatic breast cancer","volume":"4","author":"Huober","year":"2009","journal-title":"Breast Care"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1758834010388342","article-title":"Balancing the efficacy and toxicity of chemotherapy in colorectal cancer","volume":"3","author":"Braun","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: an overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2014.03.015","article-title":"Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies","volume":"84","author":"M\u00f6rth","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0030","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer (review)","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00001813-200306000-00003","article-title":"Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer","volume":"14","author":"K\u00f6nig","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0040","first-page":"825","article-title":"Management of neutropenia in cancer patients","volume":"10","author":"Lustberg","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0897190014546108","article-title":"Antineoplastic agents and the associated myelosuppressive effects: a review","volume":"27","author":"Barreto","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0050","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-006-0284-8","article-title":"Nanotechnology: intelligent design to treat complex disease","author":"Couvreur","year":"2006","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2019.04.020_bb0065","first-page":"1020","article-title":"Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development","volume":"64","author":"Pillai","year":"2014","journal-title":"SOJ Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0070","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2012.01.008","article-title":"Nanoparticle-based combination therapy toward overcoming drug resistance in cancer","volume":"83","author":"Hu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0075","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2016.03.027","article-title":"DAFODIL: a novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy","volume":"229","author":"Camacho","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005261","article-title":"A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways","volume":"7","author":"Morton","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0095","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.msec.2016.11.073","article-title":"Liposome-based drug co-delivery systems in cancer cells","volume":"71","author":"Zununi Vahed","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0100","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1073\/pnas.1406233111","article-title":"Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cocis.2017.08.002","article-title":"A review on engineering polymer drug conjugates to improve combination chemotherapy","volume":"31","author":"Vogus","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2015.04.031","article-title":"Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid","volume":"210","author":"Camacho","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2017.08.016","article-title":"A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer","volume":"267","author":"Vogus","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0120","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2009.05.006","article-title":"Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines","volume":"61","author":"Greco","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0125","article-title":"Treating tumors at low drug doses using an aptamer-peptide synergistic drug conjugate","author":"Pusuluri","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0130","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cmdc.200700121","article-title":"Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates","volume":"2","author":"Zhang","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0135","doi-asserted-by":"crossref","first-page":"9121","DOI":"10.1039\/C7TB02562A","article-title":"A carrier-free dual-drug nanodelivery system functionalized with aptamer specific targeting HER2-overexpressing cancer cells","volume":"5","author":"Jiang","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0140","doi-asserted-by":"crossref","first-page":"17939","DOI":"10.1073\/pnas.1011368107","article-title":"Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy","volume":"107","author":"Kolishetti","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0145","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1021\/nn403913k","article-title":"Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles","volume":"7","author":"Barua","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2017.03.001","article-title":"Combination antitumor therapy with targeted dual-nanomedicines","volume":"115","author":"Dai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jconrel.2006.07.012","article-title":"Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug","volume":"116","author":"Ahmed","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0160","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1002\/adfm.201401076","article-title":"Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer","volume":"24","author":"Miao","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0175","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1021\/mp200243k","article-title":"Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy","volume":"8","author":"Aryal","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/btm2.10049","article-title":"Virus-like particles: next-generation nanoparticles for targeted therapeutic delivery","volume":"2","author":"Rohovie","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/btm2.10059","article-title":"Emerging applications of exosomes in cancer therapeutics and diagnostics","volume":"2","author":"Inamdar","year":"2017","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0215","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/948501","article-title":"Human tumor antigens and cancer immunotherapy","volume":"2015","author":"Vigneron","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0225","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00441-017-2753-2","article-title":"Partners in crime: neutrophils and monocytes\/macrophages in inflammation and disease","volume":"371","author":"Prame Kumar","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0235","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26860","article-title":"Harnessing the antitumor potential of macrophages for cancer immunotherapy Kristen","volume":"2","author":"Long","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Androulla","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0255","first-page":"807","article-title":"Current landscape and future of dual anti- CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non- small cell lung cancer (NSCLC)","volume":"13","author":"Chae","year":"1994","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0260","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0265","doi-asserted-by":"crossref","first-page":"S2195","DOI":"10.21037\/jtd.2018.06.144","article-title":"Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching","volume":"10","author":"Huerter","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0270","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-017-0257-y","article-title":"Therapeutic cancer vaccines: how much closer are we?","volume":"32","author":"McNeel","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0285","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ijpharm.2017.07.075","article-title":"Promises and limitations of nanoparticles in the era of cell therapy: example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells","volume":"532","author":"Jakobczyk","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0290","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0295","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0300","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0305","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12499","article-title":"Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0320","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0325","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2015.10.002","article-title":"Anthracyclines potentiate anti-tumor immunity: a new opportunity for chemoimmunotherapy","volume":"369","author":"Zhang","year":"2015","journal-title":"Cancer Lett."},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2019.04.020_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1998.747","article-title":"New antimetabolites in cancer chemotherapy and their clinical impact","volume":"78","author":"Kaye","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0340","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00001813-200311000-00010","article-title":"Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells","volume":"14","author":"Galetto","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0345","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1189\/jlb.0109005","article-title":"Heat shock proteins and immune system","volume":"85","author":"Tsan","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0350","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0355","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00262-004-0638-1","article-title":"Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas","volume":"54","author":"Plate","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0360","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic gr-1+\/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0365","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0370","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1158\/0008-5472.CAN-07-0327","article-title":"Taxol increases the amount and T cell-activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells","volume":"67","author":"Tsuda","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0375","first-page":"3025","article-title":"Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy","volume":"7","author":"Demaria","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0380","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0385","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.yexcr.2017.12.018","article-title":"Docetaxel promotes the generation of anti-tumorigenic human macrophages","volume":"362","author":"Millrud","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0390","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0400","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s12325-016-0344-3","article-title":"Trabectedin for soft tissue sarcoma: current status and future perspectives","volume":"33","author":"Gordon","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0405","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition ofCD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0410","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2009-11-251231","article-title":"Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs","volume":"115","author":"Nakahara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/onci.22246","article-title":"Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901","volume":"2","author":"Walter","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0420","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0425","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-16-3186","article-title":"Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors","volume":"23","author":"Ratti","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0430","first-page":"471","article-title":"Understanding and improving platinum anticancer drugs","volume":"34","author":"Johnstone","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0435","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/1440-1681.12515","article-title":"Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer","volume":"43","author":"Tsai","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0440","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/bjc.2011.84","article-title":"Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis","volume":"104","author":"Duiker","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0445","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3892\/mmr.2017.6908","article-title":"Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0450","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature14395","article-title":"Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy","volume":"521","author":"Shalapour","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0455","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0460","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0465","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0470","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/OTT.S60114","article-title":"Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis","volume":"7","author":"Vyas","year":"2014","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0475","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/iai.64.3.878-884.1996","article-title":"Paclitaxel (taxol)-induced NF-kappaB translocation in murine macrophages","volume":"64","author":"Perera","year":"1996","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0480","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1158\/0008-5472.CAN-14-3525","article-title":"The role of TLR4 in chemotherapy-driven metastasis","volume":"75","author":"Ran","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0485","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1158\/0008-5472.CAN-14-0067","article-title":"Paclitaxel therapy promotes breast cancer metastasis in a TLR4- dependent manner","volume":"74","author":"Volk-draper","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0490","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1101\/gad.180331.111","article-title":"Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer","volume":"25","author":"Shree","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0495","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/onc.2009.289","article-title":"TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer","volume":"28","author":"Szajnik","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.47","article-title":"Mucin 1-mediated chemo-resistance in lung cancer cells","volume":"5","author":"Ham","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0510","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cbt.11.12.15540","article-title":"Doxorubicin and daunorubicin induce processing and release of interleukin-1\u03b2 through activation of the NLRP3 inflammasome","volume":"11","author":"Sauter","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0515","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0520","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3892\/mmr.2015.3356","article-title":"Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor \u03b2 signaling in HCT116 colon cancer cells","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nm.2652","article-title":"Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system","volume":"18","author":"Ciampricotti","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nm.2999","article-title":"Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth","volume":"19","author":"Bruchard","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0535","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-30437-2","article-title":"Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages","volume":"8","author":"Deshmukh","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0545","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0550","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.410420307","article-title":"Immune deviation following pulse cyclophosphamide\/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia","volume":"42","author":"Smith","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0555","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/0008-5472.CAN-13-3596","article-title":"Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis","volume":"74","author":"Ding","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0560","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/eji.201141639","article-title":"Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms","volume":"41","author":"Mkrtichyan","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0565","first-page":"3","article-title":"Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas","volume":"2018","author":"Lien","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0570","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0575","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0580","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ijc.27801","article-title":"Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy","volume":"132","author":"Nars","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0585","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/btm2.10082","article-title":"Schedule dependent synergy of gemcitabine and doxorubicin: improvement of in vitro efficacy and lack of in vitro-in vivo correlation","volume":"3","author":"Vogus","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0590","first-page":"3293","article-title":"Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface","volume":"20","author":"Nio","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0595","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.13-S1-5","article-title":"Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions","volume":"13","author":"Ramalingam","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0600","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-015-2947-9","article-title":"Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response","volume":"77","author":"Perroud","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0605","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3816\/CBC.2008.n.017","article-title":"A phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2\/neu-negative metastatic breast cancer","volume":"8","author":"Silva","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0610","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2014.07.033","article-title":"Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model","volume":"353","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1005521","article-title":"Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory","volume":"4","author":"Wu","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0620","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1593\/neo.101174","article-title":"Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide","volume":"13","author":"Emmenegger","year":"2011","journal-title":"Neoplasia"},{"issue":"Suppl","key":"10.1016\/j.jconrel.2019.04.020_bb0625","first-page":"OL1366","article-title":"Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk\/MAPK signaling pathway","volume":"56","author":"Qin","year":"2010","journal-title":"Cell. Mol. Biol. (Noisy-Le-Grand)"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0630","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma","volume":"5","author":"Tran","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0635","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/07357900902744510","article-title":"Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice","volume":"28","author":"Jiang","year":"2010","journal-title":"Cancer Investig."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0640","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1202781","article-title":"Anti-tumor effect of paclitaxel is mediated by inhibition of MDSCs and chronic inflammation in the spontaneous melanoma model","volume":"190","author":"Sevko","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0645","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00262-011-0988-4","article-title":"Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer","volume":"60","author":"He","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0650","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/btm2.10079","article-title":"Microfluidic co-culture devices to assess penetration of nanoparticles into cancer cell mass","volume":"2","author":"Jarvis","year":"2017","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0655","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"Hartmann","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0660","article-title":"Tumour immunogenicity, antigen presentation, and immunological barriers in cancer immunotherapy","volume":"2013","author":"Escors","year":"2014","journal-title":"New J. Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0665","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","volume":"8","author":"Decker","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0675","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/onc.2015.112","article-title":"Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors","volume":"35","author":"Haeger","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0680","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","article-title":"Humanized mouse xenograft models: narrowing the tumor-microenvironment gap","volume":"76","author":"Morton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0685","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1521s81","article-title":"Creation of \u201chumanized\u201d mice to study human immunity","author":"Pearson","year":"2008","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0695","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","article-title":"Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy","author":"Zhao","year":"2018","journal-title":"Gut."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0115-0","article-title":"Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice","volume":"50","author":"Choi","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0710","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4619-8","article-title":"Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression","volume":"18","author":"Harris","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0735","first-page":"36","article-title":"Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs","author":"Nakahara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0740","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0745","doi-asserted-by":"crossref","first-page":"44465","DOI":"10.18632\/oncotarget.17973","article-title":"M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.18542","article-title":"Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma","volume":"8","author":"Ock","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0760","article-title":"Cancer facts & figures 2018","author":"American Cancer Society","year":"2018","journal-title":"Am. Cancer Soc."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0765","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase i cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0770","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jama.292.4.470","article-title":"Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non\u2013small-cell lung cancer","volume":"292","author":"Delbaldo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0775","article-title":"Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer","volume":"2015","author":"Resende","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0780","first-page":"1535","article-title":"Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis","volume":"9","author":"Wu","year":"2016","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0785","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/02841860117846","article-title":"A systematic overview of chemotherapy effects in pancreatic cancer","volume":"40","author":"Johan Permert","year":"2001","journal-title":"Acta Oncol. (Madr)."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0790","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1054\/bjoc.2000.1399","article-title":"Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines","volume":"83","author":"Kroep","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0795","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF01195344","article-title":"Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine","volume":"119","author":"Rowinsky","year":"1993","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0800","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17474086.2017.1369400","article-title":"CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?","volume":"10","author":"Brunetti","year":"2017","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0805","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0810","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/mi.7.4.8","article-title":"Optimizing combination chemotherapy by controlling drug ratios","volume":"7","author":"Mayer","year":"2007","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0815","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.201242505","article-title":"Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response","volume":"43","author":"Hannesd\u00f3ttir","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0820","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0825","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00262-009-0749-9","article-title":"The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy","volume":"59","author":"Wu","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0830","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0835","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3111\/13696998.2011.556693","article-title":"A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer","volume":"14","author":"Nelson","year":"2011","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0840","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.21411","article-title":"Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma","volume":"104","author":"Hillner","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0845","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-17-3102","article-title":"Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance","volume":"78","author":"Hibino","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0850","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1179\/joc.2007.19.6.716","article-title":"Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens","volume":"19","author":"Wijayahadi","year":"2007","journal-title":"J. Chemother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0855","first-page":"23","article-title":"Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing","volume":"27","author":"Gameiro","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0860","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002620100229","article-title":"Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes","volume":"50","author":"Bergmann-Leitner","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0865","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/onc.2010.500","article-title":"Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress","volume":"30","author":"Martins","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0870","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-05-1761","article-title":"Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis","volume":"12","author":"Gelbard","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0875","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.bjc.6690449","article-title":"Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-\u03baB independent pathway","volume":"80","author":"Takizawa","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0880","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/0300060514561504","article-title":"Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer","volume":"43","author":"Chen","year":"2015","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0885","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0890","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0895","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0900","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003807","article-title":"Cardiac glycosides exert anticancer effects by inducing immunogenic cell death","volume":"4","author":"Menger","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0905","first-page":"210","article-title":"Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model","volume":"27","author":"Chen","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0910","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1040-8428(00)00070-6","article-title":"Oxaliplatin clinical activity: a review","volume":"35","author":"Misset","year":"2000","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0915","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0920","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-009-0797-1","article-title":"Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma","volume":"59","author":"Tongu","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0925","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3677-7","article-title":"A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0935","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","article-title":"Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages","volume":"132","author":"Buhtoiarov","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0940","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0945","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.vaccine.2009.02.018","article-title":"Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine","volume":"27","author":"Montero","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0950","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor - secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation","volume":"27","author":"Emens","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0955","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0960","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.0803773","article-title":"In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy","volume":"183","author":"Li","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0965","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2147\/OTT.S127955","article-title":"Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas","volume":"10","author":"Recine","year":"2017","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0970","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543784.12.11.1843","article-title":"Preclinical and clinical results with the natural marine product ET-743","volume":"12","author":"D'Incalci","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0975","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neo.2017.03.004","article-title":"Trabectedin and campthotecin synergistically eliminate cancer stem cells in cell-of-origin sarcoma models","volume":"19","author":"Martinez-Cruzado","year":"2017","journal-title":"Neoplasia (United States)"},{"key":"10.1016\/j.jconrel.2019.04.020_bb0980","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.2015.65.3329","article-title":"Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma study","volume":"34","author":"Martin-Broto","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0985","first-page":"3251","article-title":"Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0990","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-003-0636-6","article-title":"Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies","volume":"52","author":"Meco","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb0995","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1000","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/eji.201444722","article-title":"Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy","volume":"45","author":"Mcdonnell","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1005","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-Tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1010","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tiv.2017.02.019","article-title":"Role of toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro","volume":"41","author":"Mallick","year":"2017","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/dmd.107.018051","article-title":"Regulation of hepatic drug-metabolizing enzyme genes by toll-like receptor 4 signaling is independent of toll-interleukin 1 receptor domain-containing adaptor protein","volume":"36","author":"Ghose","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jconrel.2019.04.020_bb1025","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4161\/onci.22009","article-title":"Trial watch prognostic and predictive value of the immune infiltrate in cancer","author":"Senovilla","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1030","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/0008-5472.CAN-05-3523","article-title":"Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts","volume":"66","author":"Paulus","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1035","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.4161\/onci.21684","article-title":"Anticancer activity of cardiac glycosides: at the frontier between cell-autonomous and immunological effects","volume":"1","author":"Kepp","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0105907","article-title":"Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients","volume":"9","author":"Mignot","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065181","article-title":"Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells","volume":"8","author":"Bugaut","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13198","article-title":"Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy","volume":"168","author":"Romano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1060","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u0392-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1070","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-9-139","article-title":"Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas","volume":"9","author":"Bergmann","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4161\/onci.18684","article-title":"Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1085","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","article-title":"Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis","volume":"45","author":"Zhang","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1090","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1095","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","article-title":"PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"3","author":"Wimberly","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejpb.2010.05.002","article-title":"Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?","volume":"76","author":"Al-Hallak","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1110","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1158\/0008-5472.CAN-13-0987","article-title":"Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biomaterials.2018.09.023","article-title":"Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment","volume":"186","author":"Arroyo-Crespo","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.11.021","article-title":"Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity","volume":"269","author":"Mastria","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acs.molpharmaceut.6b00932","article-title":"Inducing optimal antitumor immune response through coadministering iRGD with pirarubicin loaded nanostructured lipid carriers for breast cancer therapy","volume":"14","author":"Deng","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biomaterials.2016.09.001","article-title":"Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment","volume":"108","author":"Song","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1140","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-1016-03","article-title":"Cellular immunity in breast cancer patients completing taxane treatment","volume":"10","author":"Carson","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","article-title":"Immunomodulatory activity of VEGF in cancer","volume":"330","author":"Lapeyre-Prost","year":"2017","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2009.08.020","article-title":"Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer","volume":"619","author":"Fioravanti","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/1521-3900(200107)172:1<21::AID-MASY21>3.0.CO;2-C","article-title":"Immunoprotective therapy with targeted anticancer drugs","volume":"172","author":"\u0158\u00edhov\u00e1","year":"2001","journal-title":"Macromol. Symp."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","article-title":"Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy","volume":"102","author":"Zhao","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1165","first-page":"4569","article-title":"Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity","volume":"31","author":"Maeda","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-013-1502-y","article-title":"The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer","volume":"63","author":"Annels","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1175","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41416-018-0085-y","article-title":"Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer","volume":"118","author":"Kalanxhi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1180","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biomaterials.2013.10.003","article-title":"Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response","volume":"35","author":"Thomas","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2016.05.025","article-title":"Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: a combination nanomedicine approach","volume":"379","author":"Lu","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2016.12.003","article-title":"Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer","volume":"176","author":"Zirakzadeh","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1200","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0090-4295(00)00524-0","article-title":"Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy","volume":"55","author":"Krainer","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/CVI.00292-09","article-title":"Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model","volume":"17","author":"Kim","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1210","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1215","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood.V97.8.2420","article-title":"The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses","volume":"97","author":"Runyon","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-3659(01)00489-8","article-title":"Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs","volume":"78","author":"PiHova","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1230","doi-asserted-by":"crossref","first-page":"20071","DOI":"10.1073\/pnas.1206360109","article-title":"Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response","volume":"109","author":"Beneteau","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-391858-1.00008-3","article-title":"Targeting nanoparticles to dendritic cells for immunotherapy","volume":"509","author":"Cruz","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120638","article-title":"A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer","volume":"3","author":"Cheng","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1250","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1255","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nmat2569","article-title":"Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection","volume":"8","author":"Andrew MacKay","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1260","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.carbpol.2013.02.018","article-title":"Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment","volume":"94","author":"Lee","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1265","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.colsurfb.2012.11.046","article-title":"PST-gold nanoparticle as an effective anticancer agent with immunomodulatory properties","volume":"104","author":"Joseph","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1270","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.2174\/09298673113206660281","article-title":"HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death","volume":"20","author":"Sirova","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1275","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/mp100121g","article-title":"Synergistic action of doxorubicin bound to the polymeric carrier based on N- (2-Hydroxypropyl) methacrylamide copolymers through an amide or hydrazone bond","volume":"7","author":"Etrych","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1280","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0022-3565(24)36522-X","article-title":"The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors","volume":"280","author":"Mayer","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9692","article-title":"Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug","volume":"6","author":"Miller","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1290","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1039\/C4PY00369A","article-title":"Camptothecin prodrug block copolymer micelles with high drug loading and target specificity","volume":"5","author":"Khan","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1295","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1300","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1073\/pnas.0804897106","article-title":"Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome","volume":"106","author":"Sharp","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1305","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1310","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","article-title":"A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0567-0","article-title":"Improved natural killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy","volume":"13","author":"Muraro","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1320","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaoncol.2016.6007","article-title":"Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1325","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2017.12.001","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes","volume":"73","author":"Galsky","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1330","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4161\/onci.1.2.19026","article-title":"Trial watch: chemotherapy with immunogenic cell death inducers","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1335","first-page":"479","article-title":"Efficacy and toxicity of low-dose versus conventional-dose chemotherapy for malignant tumors: a meta-analysis of 6 randomized controlled trials","volume":"18","author":"Xie","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1340","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1345","first-page":"1","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"L.","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2016.12.180","article-title":"Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model","volume":"487","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1355","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-013-1451-5","article-title":"Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models","volume":"62","author":"Jure-Kunkel","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1365","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00262-012-1345-y","article-title":"Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response","volume":"62","author":"Diaz","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1370","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biomaterials.2013.09.050","article-title":"Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells","volume":"35","author":"Sunshine","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1375","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/en.2009-1082","article-title":"Minireview: nanoparticles and the immune system","volume":"151","author":"Zolnik","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1380","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1385","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.04.020_bb1390","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"wen Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.04.020_bb1395","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919302202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919302202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:41:16Z","timestamp":1759160476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919302202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":270,"alternative-id":["S0168365919302202"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}